Cargando…
Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
PURPOSE: To report the effects of aflibercept on eyes with large retinal pigment epithelial detachment (PED) associted with polypoidal choroidal vasculopathy (PCV). METHODS: We reviewed the medical records of patients with PEDs associated with PCV that were treated with aflibercept after intravitrea...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935506/ https://www.ncbi.nlm.nih.gov/pubmed/24591809 http://dx.doi.org/10.2147/OPTH.S56539 |
_version_ | 1782305197516652544 |
---|---|
author | Yamashita, Mariko Nishi, Tomo Hasegawa, Taiji Ogata, Nahoko |
author_facet | Yamashita, Mariko Nishi, Tomo Hasegawa, Taiji Ogata, Nahoko |
author_sort | Yamashita, Mariko |
collection | PubMed |
description | PURPOSE: To report the effects of aflibercept on eyes with large retinal pigment epithelial detachment (PED) associted with polypoidal choroidal vasculopathy (PCV). METHODS: We reviewed the medical records of patients with PEDs associated with PCV that were treated with aflibercept after intravitreal ranibizumab had failed. RESULTS: Three eyes of patients aged 72, 79, and 80 years were studied. Reflective material was seen in the PED along the outer surface of the retinal pigment epithelium (RPE) by spectral-domain optical coherence tomography (SD-OCT). A complete resolution of the serous PEDs was found after two aflibercept injections; however, all eyes had a fibrovascular PED. In addition, one eye developed a retinal hemorrhage and a recurrent PED just after the third injection of aflibercept. The visual acuity in this eye decreased from 10/20 to 2/20. CONCLUSION: The reflective material below the outer surface of the RPE in serous PED suggests the presence of neovascularization. Intravitreal aflibercept could be considered for large PEDs in eyes with PCV but should be carefully applied. |
format | Online Article Text |
id | pubmed-3935506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-39355062014-03-03 Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab Yamashita, Mariko Nishi, Tomo Hasegawa, Taiji Ogata, Nahoko Clin Ophthalmol Case Report PURPOSE: To report the effects of aflibercept on eyes with large retinal pigment epithelial detachment (PED) associted with polypoidal choroidal vasculopathy (PCV). METHODS: We reviewed the medical records of patients with PEDs associated with PCV that were treated with aflibercept after intravitreal ranibizumab had failed. RESULTS: Three eyes of patients aged 72, 79, and 80 years were studied. Reflective material was seen in the PED along the outer surface of the retinal pigment epithelium (RPE) by spectral-domain optical coherence tomography (SD-OCT). A complete resolution of the serous PEDs was found after two aflibercept injections; however, all eyes had a fibrovascular PED. In addition, one eye developed a retinal hemorrhage and a recurrent PED just after the third injection of aflibercept. The visual acuity in this eye decreased from 10/20 to 2/20. CONCLUSION: The reflective material below the outer surface of the RPE in serous PED suggests the presence of neovascularization. Intravitreal aflibercept could be considered for large PEDs in eyes with PCV but should be carefully applied. Dove Medical Press 2014-03-02 /pmc/articles/PMC3935506/ /pubmed/24591809 http://dx.doi.org/10.2147/OPTH.S56539 Text en © 2014 Yamashita et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Case Report Yamashita, Mariko Nishi, Tomo Hasegawa, Taiji Ogata, Nahoko Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab |
title | Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab |
title_full | Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab |
title_fullStr | Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab |
title_full_unstemmed | Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab |
title_short | Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab |
title_sort | response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935506/ https://www.ncbi.nlm.nih.gov/pubmed/24591809 http://dx.doi.org/10.2147/OPTH.S56539 |
work_keys_str_mv | AT yamashitamariko responseofserousretinalpigmentepithelialdetachmentstointravitrealafliberceptinpolypoidalchoroidalvasculopathyrefractorytoranibizumab AT nishitomo responseofserousretinalpigmentepithelialdetachmentstointravitrealafliberceptinpolypoidalchoroidalvasculopathyrefractorytoranibizumab AT hasegawataiji responseofserousretinalpigmentepithelialdetachmentstointravitrealafliberceptinpolypoidalchoroidalvasculopathyrefractorytoranibizumab AT ogatanahoko responseofserousretinalpigmentepithelialdetachmentstointravitrealafliberceptinpolypoidalchoroidalvasculopathyrefractorytoranibizumab |